WGU D116 Advanced Pharmacology OA
ACTUAL EXAM 2026/2027 | Verified Questions
Correct Answers | Verified Q&A | Pass
Guaranteed - A+ Graded
Cluster 1: Pharmacokinetics, Pharmacodynamics & Core Principles
Q1: A patient is prescribed a new medication that is primarily metabolized by the CYP3A4 enzyme in the
liver. The patient is also taking ketoconazole, a known CYP3A4 inhibitor. Which pharmacokinetic effect is
most likely to occur?
A. Decreased plasma concentration of the new medication due to increased metabolism.
B. Increased plasma concentration of the new medication due to decreased metabolism, potentially
leading to toxicity.
C. No change in plasma concentration because CYP3A4 inhibition only affects drug absorption.
D. Increased renal excretion of the new medication.
B. Increased plasma concentration of the new medication due to decreased metabolism, potentially
leading to toxicity. [CORRECT]
Correct Answer: B
Rationale: The correct answer is B because ketoconazole is a potent CYP3A4 inhibitor — when CYP3A4 is
inhibited, the metabolism of drugs dependent on this enzyme is slowed, leading to increased plasma
concentrations, prolonged half-life, and increased risk of adverse effects or toxicity; this is a critical drug-
drug interaction that requires dose adjustment or alternative therapy. Remember that when a patient is
on multiple medications, we need to consider potential drug-drug interactions, especially with CYP450
enzyme inducers/inhibitors.
Q2: A patient is started on a medication with a narrow therapeutic index. Which statement best
describes the clinical significance of this pharmacokinetic characteristic?
,A. The drug is safe at any dose because the therapeutic and toxic doses are far apart.
B. Small changes in drug concentration can lead to either therapeutic failure or toxicity, requiring careful
monitoring of drug levels.
C. The drug has a very long half-life and requires only once-weekly dosing.
D. The drug is rapidly metabolized and requires frequent dosing.
B. Small changes in drug concentration can lead to either therapeutic failure or toxicity, requiring
careful monitoring of drug levels. [CORRECT]
Correct Answer: B
Rationale: The correct answer is B because a narrow therapeutic index means the difference between
the minimum effective concentration and the minimum toxic concentration is small — drugs like
digoxin, lithium, warfarin, and phenytoin require therapeutic drug monitoring, precise dosing, and
vigilant monitoring for signs of toxicity or subtherapeutic levels. This aligns with the WGU D116
expectation that students can evaluate pharmacotherapy in the context of individual patient
characteristics.
Q3: A patient is prescribed a medication that follows first-order kinetics. If the half-life of the drug is 6
hours, approximately how long will it take to reach steady-state plasma concentration?
A. 6 hours
B. 12 hours
C. 24–30 hours
D. 48 hours
C. 24–30 hours [CORRECT]
Correct Answer: C
Rationale: The correct answer is C because steady-state concentration is typically reached after
approximately 4–5 half-lives — with a 6-hour half-life, 5 half-lives equals 30 hours; at steady state, the
rate of drug administration equals the rate of elimination, and plasma concentrations plateau within the
therapeutic range. Remember that when a patient is on multiple medications, we need to consider
potential drug-drug interactions, especially with CYP450 enzyme inducers/inhibitors.
Q4: A patient with renal impairment is prescribed a drug that is primarily excreted unchanged by the
kidneys. Which nursing action is most appropriate?
,A. Administer the standard dose because renal impairment does not affect drug excretion.
B. Reduce the dose or extend the dosing interval to prevent drug accumulation and toxicity.
C. Increase the dose to compensate for reduced renal clearance.
D. Switch to an intravenous route to bypass renal excretion.
B. Reduce the dose or extend the dosing interval to prevent drug accumulation and toxicity.
[CORRECT]
Correct Answer: B
Rationale: The correct answer is B because drugs excreted primarily by the kidneys accumulate in renal
impairment — reduced glomerular filtration rate decreases clearance, prolongs half-life, and increases
the risk of toxicity; dose reduction or interval extension based on creatinine clearance is essential for
patient safety with renally eliminated drugs like aminoglycosides, vancomycin, and digoxin. This aligns
with the WGU D116 expectation that students can evaluate pharmacotherapy in the context of
individual patient characteristics.
Q5: A patient is taking warfarin and starts eating large amounts of leafy green vegetables. Which
pharmacodynamic effect is most likely to occur?
A. Increased INR due to vitamin K potentiation of warfarin.
B. Decreased INR due to dietary vitamin K antagonizing warfarin's anticoagulant effect.
C. No effect because dietary vitamin K does not affect warfarin pharmacodynamics.
D. Increased risk of bleeding due to additive anticoagulant effects.
B. Decreased INR due to dietary vitamin K antagonizing warfarin's anticoagulant effect. [CORRECT]
Correct Answer: B
Rationale: The correct answer is B because warfarin is a vitamin K antagonist that inhibits the synthesis
of vitamin K-dependent clotting factors — dietary vitamin K is an essential cofactor for the synthesis of
these clotting factors, and increased intake can overcome warfarin's inhibitory effect, leading to a
decreased INR and potentially subtherapeutic anticoagulation; patients on warfarin need consistent
vitamin K intake. Remember that when a patient is on multiple medications, we need to consider
potential drug-drug interactions, especially with CYP450 enzyme inducers/inhibitors.
Q6: A patient is prescribed a prodrug that requires activation by hepatic enzymes to its active
metabolite. The patient has severe liver disease. Which clinical concern is most important?
, A. The drug will be excessively potent due to increased hepatic metabolism.
B. The drug may not be adequately activated, leading to subtherapeutic effects.
C. The drug will be rapidly excreted by the kidneys before activation.
D. The drug will cause direct hepatotoxicity unrelated to metabolism.
B. The drug may not be adequately activated, leading to subtherapeutic effects. [CORRECT]
Correct Answer: B
Rationale: The correct answer is B because prodrugs like codeine (converted to morphine by CYP2D6)
and enalapril (converted to enalaprilat) require hepatic metabolism for activation — in severe liver
disease, impaired enzyme function reduces conversion to the active form, leading to inadequate
therapeutic response; alternative drugs that do not require hepatic activation should be considered. This
aligns with the WGU D116 expectation that students can evaluate pharmacotherapy in the context of
individual patient characteristics.
Q7: A patient is a poor metabolizer of CYP2D6. Which medication would be most affected by this
pharmacogenomic variation?
A. Acetaminophen
B. Codeine (requires CYP2D6 conversion to morphine for analgesic effect)
C. Aspirin
D. Ibuprofen
B. Codeine (requires CYP2D6 conversion to morphine for analgesic effect) [CORRECT]
Correct Answer: B
Rationale: The correct answer is B because codeine is a prodrug that requires CYP2D6-mediated O-
demethylation to convert to morphine, the active analgesic — poor metabolizers have reduced or
absent CYP2D6 activity, resulting in minimal morphine production and inadequate pain relief; ultrarapid
metabolizers, conversely, may produce excessive morphine and experience toxicity or respiratory
depression. Remember that when a patient is on multiple medications, we need to consider potential
drug-drug interactions, especially with CYP450 enzyme inducers/inhibitors.
Q8: A patient experiences an anaphylactic reaction after receiving penicillin. Which type of adverse drug
reaction is this?
ACTUAL EXAM 2026/2027 | Verified Questions
Correct Answers | Verified Q&A | Pass
Guaranteed - A+ Graded
Cluster 1: Pharmacokinetics, Pharmacodynamics & Core Principles
Q1: A patient is prescribed a new medication that is primarily metabolized by the CYP3A4 enzyme in the
liver. The patient is also taking ketoconazole, a known CYP3A4 inhibitor. Which pharmacokinetic effect is
most likely to occur?
A. Decreased plasma concentration of the new medication due to increased metabolism.
B. Increased plasma concentration of the new medication due to decreased metabolism, potentially
leading to toxicity.
C. No change in plasma concentration because CYP3A4 inhibition only affects drug absorption.
D. Increased renal excretion of the new medication.
B. Increased plasma concentration of the new medication due to decreased metabolism, potentially
leading to toxicity. [CORRECT]
Correct Answer: B
Rationale: The correct answer is B because ketoconazole is a potent CYP3A4 inhibitor — when CYP3A4 is
inhibited, the metabolism of drugs dependent on this enzyme is slowed, leading to increased plasma
concentrations, prolonged half-life, and increased risk of adverse effects or toxicity; this is a critical drug-
drug interaction that requires dose adjustment or alternative therapy. Remember that when a patient is
on multiple medications, we need to consider potential drug-drug interactions, especially with CYP450
enzyme inducers/inhibitors.
Q2: A patient is started on a medication with a narrow therapeutic index. Which statement best
describes the clinical significance of this pharmacokinetic characteristic?
,A. The drug is safe at any dose because the therapeutic and toxic doses are far apart.
B. Small changes in drug concentration can lead to either therapeutic failure or toxicity, requiring careful
monitoring of drug levels.
C. The drug has a very long half-life and requires only once-weekly dosing.
D. The drug is rapidly metabolized and requires frequent dosing.
B. Small changes in drug concentration can lead to either therapeutic failure or toxicity, requiring
careful monitoring of drug levels. [CORRECT]
Correct Answer: B
Rationale: The correct answer is B because a narrow therapeutic index means the difference between
the minimum effective concentration and the minimum toxic concentration is small — drugs like
digoxin, lithium, warfarin, and phenytoin require therapeutic drug monitoring, precise dosing, and
vigilant monitoring for signs of toxicity or subtherapeutic levels. This aligns with the WGU D116
expectation that students can evaluate pharmacotherapy in the context of individual patient
characteristics.
Q3: A patient is prescribed a medication that follows first-order kinetics. If the half-life of the drug is 6
hours, approximately how long will it take to reach steady-state plasma concentration?
A. 6 hours
B. 12 hours
C. 24–30 hours
D. 48 hours
C. 24–30 hours [CORRECT]
Correct Answer: C
Rationale: The correct answer is C because steady-state concentration is typically reached after
approximately 4–5 half-lives — with a 6-hour half-life, 5 half-lives equals 30 hours; at steady state, the
rate of drug administration equals the rate of elimination, and plasma concentrations plateau within the
therapeutic range. Remember that when a patient is on multiple medications, we need to consider
potential drug-drug interactions, especially with CYP450 enzyme inducers/inhibitors.
Q4: A patient with renal impairment is prescribed a drug that is primarily excreted unchanged by the
kidneys. Which nursing action is most appropriate?
,A. Administer the standard dose because renal impairment does not affect drug excretion.
B. Reduce the dose or extend the dosing interval to prevent drug accumulation and toxicity.
C. Increase the dose to compensate for reduced renal clearance.
D. Switch to an intravenous route to bypass renal excretion.
B. Reduce the dose or extend the dosing interval to prevent drug accumulation and toxicity.
[CORRECT]
Correct Answer: B
Rationale: The correct answer is B because drugs excreted primarily by the kidneys accumulate in renal
impairment — reduced glomerular filtration rate decreases clearance, prolongs half-life, and increases
the risk of toxicity; dose reduction or interval extension based on creatinine clearance is essential for
patient safety with renally eliminated drugs like aminoglycosides, vancomycin, and digoxin. This aligns
with the WGU D116 expectation that students can evaluate pharmacotherapy in the context of
individual patient characteristics.
Q5: A patient is taking warfarin and starts eating large amounts of leafy green vegetables. Which
pharmacodynamic effect is most likely to occur?
A. Increased INR due to vitamin K potentiation of warfarin.
B. Decreased INR due to dietary vitamin K antagonizing warfarin's anticoagulant effect.
C. No effect because dietary vitamin K does not affect warfarin pharmacodynamics.
D. Increased risk of bleeding due to additive anticoagulant effects.
B. Decreased INR due to dietary vitamin K antagonizing warfarin's anticoagulant effect. [CORRECT]
Correct Answer: B
Rationale: The correct answer is B because warfarin is a vitamin K antagonist that inhibits the synthesis
of vitamin K-dependent clotting factors — dietary vitamin K is an essential cofactor for the synthesis of
these clotting factors, and increased intake can overcome warfarin's inhibitory effect, leading to a
decreased INR and potentially subtherapeutic anticoagulation; patients on warfarin need consistent
vitamin K intake. Remember that when a patient is on multiple medications, we need to consider
potential drug-drug interactions, especially with CYP450 enzyme inducers/inhibitors.
Q6: A patient is prescribed a prodrug that requires activation by hepatic enzymes to its active
metabolite. The patient has severe liver disease. Which clinical concern is most important?
, A. The drug will be excessively potent due to increased hepatic metabolism.
B. The drug may not be adequately activated, leading to subtherapeutic effects.
C. The drug will be rapidly excreted by the kidneys before activation.
D. The drug will cause direct hepatotoxicity unrelated to metabolism.
B. The drug may not be adequately activated, leading to subtherapeutic effects. [CORRECT]
Correct Answer: B
Rationale: The correct answer is B because prodrugs like codeine (converted to morphine by CYP2D6)
and enalapril (converted to enalaprilat) require hepatic metabolism for activation — in severe liver
disease, impaired enzyme function reduces conversion to the active form, leading to inadequate
therapeutic response; alternative drugs that do not require hepatic activation should be considered. This
aligns with the WGU D116 expectation that students can evaluate pharmacotherapy in the context of
individual patient characteristics.
Q7: A patient is a poor metabolizer of CYP2D6. Which medication would be most affected by this
pharmacogenomic variation?
A. Acetaminophen
B. Codeine (requires CYP2D6 conversion to morphine for analgesic effect)
C. Aspirin
D. Ibuprofen
B. Codeine (requires CYP2D6 conversion to morphine for analgesic effect) [CORRECT]
Correct Answer: B
Rationale: The correct answer is B because codeine is a prodrug that requires CYP2D6-mediated O-
demethylation to convert to morphine, the active analgesic — poor metabolizers have reduced or
absent CYP2D6 activity, resulting in minimal morphine production and inadequate pain relief; ultrarapid
metabolizers, conversely, may produce excessive morphine and experience toxicity or respiratory
depression. Remember that when a patient is on multiple medications, we need to consider potential
drug-drug interactions, especially with CYP450 enzyme inducers/inhibitors.
Q8: A patient experiences an anaphylactic reaction after receiving penicillin. Which type of adverse drug
reaction is this?
